Revisitation of the clinical indications for the transfusion of platelet concentrates

Reviews in Clinical and Experimental Hematology

Volumn 5, Issue 3, 2001, Pages 288-310

  Rebulla, Paolo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ALLOGENEIC RESTRICTION; APHERESIS; BLEEDING; CANCER PATIENT; CLINICAL EXAMINATION; DAILY LIFE ACTIVITY; EMERGENCY TREATMENT; HUMAN; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION;

GUIDELINES; HUMANS; LEUKOCYTES; PLATELET TRANSFUSION; PLATELETPHERESIS; QUALITY CONTROL; STERILIZATION;

EID: 0035467579     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2001.00042.x     Document Type: Review

References (164)

1. Effect of platelet transfusion on hemorrhage in patients with acute leukemia
2. Platelet transfusion therapy for the cancer patient
3. Principles of platelet transfusion therapy
4. Use of platelets and other transfusion products in patients with malignancy
5. The rational use of platelet transfusions in children
6. Platelet transfusion therapy
7. Current practice and guidelines for the transfusion of cellular blood components in the newborn
8. Guidelines for platelet transfusion
9. Practice parameters for the use of fresh-frozen plasma, cryoprecipitate, and platelets
10. Practice guidelines for blood component therapy
11. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-hostdisease
12. Guidelines on the clinical use of leucocyte-depleted blood components
13. Consensus conference on platelet transfusion, Royal College of Physicians of Edinburgh, 27-28. November 1997: Synopsis of background papers
14. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology
15. Hemostatic drugs
16. Current status of non-transfusional haemostatic agents
17. Pharmacological therapies to minimise platelet transfusion
18. Unexpected bleeding disorders: Algorithms for approach to therapy
19. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood
20. Plateletpheresis comparison of platelet yields, processing time, and white cell content with two apheresis systems
21. Current instrumentation for apheresis
22. Comparison of COBE white cellreduction and standard plateletpheresis protocols in the same donors
23. Platelet transfusion therapy
24. The risk of acquiring transfusion-transmissible infections
25. Delayed alloimmunization by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia
26. Delayed alloimmunization using random single donor platelet transfusions: A prospective study in thrombocytopenic patients with acute leukemia
27. Alloimmunization following apheresis platelets vs pooled platelet concentrates transfusion - A prospective randomized study
28. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
29. Considerations in the selection of a platelet component: Apheresis versus whole blood-derived
30. The risk of transfusion transmitted viral infections
31. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets
32. Pooled platelet concentrates: Maybe not fancy, but fiscally sound and effective
33. Single donor platelets: Can we afford to use them? Can we afford not to use them?
34. High-yield platelet concentrates attainable by continuous quality improvement reduce platelet transfusion cost and donor exposure
35. A comparative analysis of different methods for routine blood component preparation
36. Prevention of microaggregate formation by removal of "buffycoats"
37. Platelet concentrates stored in plasma for 72 hours at 22°C prepared from buffycoats of citratephosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucosemannitol system
38. Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium
39. Platelet concentrates prepared from pooled buffy-coats and stored in a glucose-free crystalloid medium. The Milan experience
40. Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium
41. The selection of plastic materials for blood bags
42. Extended storage of single-donor apheresis platelets in CLX blood bags: Effect of storage on platelet morphology, viability, and in vitro function
43. Improvement of platelet storage conditions by using new polyolefin containers
44. Quality of pooled platelet concentrates prepared from buffy coats and stored in an additive solution after filtration
45. Platelet concentrates in an additive solution prepared from pooled bully coats
46. Platelet storage for transfusion in synthetic media: Further optimization of ingredients and definition of their roles
47. Role of acetate during platelet storage in a synthetic medium
48. Additive solutions for the storage of platelets for transfusion
49. An investigation of nonhemolytic transfusion reactions
50. Reactions reported to red blood cells without buffy-coat and to platelet concentrates prepared from buffs-coats
51. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats
52. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: A prospective, randomized study
53. 52Cr
54. Therapeutic effectiveness of frozen platelet concentrates for transfusion
55. Cryopreservation of platelets isolated with the IBM 2997 blood cell separator: A rapid and simplified approach
56. Frozen platelets and platelet substitutes in transfusion medicine
57. Human platelets frozen with glycerol in liquid nitrogen: Biological and clinical aspects
58. Cryopreservation of platelets: An in-vitro comparison of four methods
59. Platelet cryopreservation using dimethylsulfoxide/polyethylene glycol/sugar mixture as cryopreserving solution
60. Effects of the addition of second-messenger effectors to platelet concentrates separated from whole-blood donations and stored at 4 degrees C or -80 degrees C
61. Platelet cryopreservation using a combination of epinephrine and dimethyl sulfoxide as cryoprotectants
62. Frozen autologous platelet transfusion for patients with leukemia
63. Bleeding prophylaxis in autologous bone marrow transplantation for solid tumors. Comparison of cryopreserved autologous and fresh allogeneic single-donor platelets
64. Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulfoxide in patients with severe thrombocytopenia: A pilot study
65. Leukocyte reduction in blood component therapy
66. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration
67. Prevention of alloimmunization against platelets
68. Should all platelets concentrates issued be leukocyte-poor?
69. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs
70. The efficacy of leukodepletion to improve platelet transfusion response: A critical appraisal of clinical studies
71. Costeffectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia
72. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes
73. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
74. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood
75. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
76. Transmission of adult T-cell leukemia vires (HTLV-I) through blood transfusion and its prevention
77. Reduction of human immunodeficiency virus-infected cells from donor blood by leukocyte filtration
78. Transfusion reactions in thalassemia. A survey from the COOLEYCARE programme
79. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions
80. Febrile reactions to platelet transfusions
81. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration
82. Febrile reactions after platelet transfusion: The effect of single versus multiple donors
83. Increased tumor necrosis factor a (TNFa), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: Relationship between TNFa and IL-6 levels and febrile transfusion reactions
84. Cytokine generation in stored platelet concentrates
85. Febrile reactions to platelet transfusion: The effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method
86. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates
87. Is the febrile response to transfusion due to donor or recipient cytokine?
88. Evidence-based medicine: The case for white cell reduction
89. Universal WBC reduction
90. HLA-homozygous donors and transfusionassociated graft-versus-host disease
91. Transfusionassociated graft-versus-host disease
92. Successful treatment of transfusion-associated graft-versus-host disease
93. Transfusion-associated graft-versus-host disease in a presumed immunocompetent patient
94. Posttransfusion graft-versus-host disease in immunocompetent patients after cardiac surgery in Japan
95. Transfusion-associated graft-versus-host disease in an immunocompetent patient
96. A case of transfusion-associated graftversus-host disease not prevented by white cell-reduction filters
97. Clinical evaluation of the effects of storage time and irradiation on transfused platelets
98. The influence of irradiation on stored platelets
99. Storage of apheresis platelets after gamma radiation
100. Variation in blood component irradiation practice: Implications for prevention of transfusion-associated graft-versus-host disease
101. Bacterial contamination of single-donor blood components
102. Progress in improving the pathogen safety of red cell concentrates
103. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates
104. The use of riboflavin for the inactivation of pathogens in blood products
105. Summary of a workshop on in vivo efficacy of transfused platelet components and platelet substitutes
106. Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex
107. Lyophilized platelets: Nearing clinical trials
108. Intracellular function in rehydrated lyophilized platelets
109. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits
110. Metodi di preparazione, Volume e contenuto di emoglobina, piastrine e leucociti negli emocomponenti prodotti in 15 centri trasfusionali italiani
111. In vitro assessment of platelet function
112. In vitro assessment of the quality of stored platelet concentrates
113. Assessment of swirling and percent discs by oil, phase microscopy as quality control procedures for platelet concentrates
114. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice
115. Enhanced flow cytometric method for counting very low numbers of white cells in platelet products
116. Large-Volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC-reduced platelets: Validation and application for quality control of WBC-reduced platelets prepared by apheresis and filtration
117. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients
118. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study
119. Indications for platelet transfusion in children with acute leukemia
120. The quantitative relation between platelet counts and hemorrhage in patients with acute leukemia
121. Thrombocytopenia mechanisms and management of defects in platelet production
122. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia
123. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution
124. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10000/μL versus 20000/μL
125. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
126. 9/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
127. Lowering the prophylactic platelet transfusion threshold: A prospective analysis
128. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia
129. Automated platelet counters. A comparative evaluation of the latest instrumentation
130. Accuracy of low platelet counts on the Coulter S-Plus IV
131. Estimation of the lower limits of manual and automated platelet counting
132. Automated CD61 immunoplatelet analysis of thrombocytopenic samples
133. Thrombocytopenia and gastrointestinal hemorrhage in the cancer patient: Prevalence of unmasked lesions
134. Surgery, in acute leukemia. A review of 167 operations in thrombocytopenic patients
135. The significance of thrombocytopenia in the development of perioperative intracranial hematoma
136. Complications of fiberoptic bronchoscopy in thrombocytopenic patients
137. Platelet transfusion therapy in newborn infants
138. Management of acquired coagulation disorders in emergency and intensive-care medicine
139. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia
140. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors
141. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities
142. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient
143. Blood component therapy in open heart surgery
144. The management of abnormalities of hemostasis in acute liver failure
145. Hemorrhagic complications in the newborn
146. Platelet transfusions: Utilization and associated costs in a tertiary care hospital
147. A semiautomated platelet cross-matching system for the management of platelet refractoriness
148. Glanzmann's thrombasthenia: The spectrum of clinical disease
149. Platelet transfusion in a patient affected by Glanzmann's thrombasthenia with antibodies against GPIIb-IIIa
150. Pregnancy in a patient of Glanzmann's thrombasthenia with antiplatelet antibodies
151. Disseminated intravascular coagulation: Diagnosis and treatment
152. Management of thrombotic thrombocytopenic purpura
153. Consensus conference on platelet transfusion. Indications for therapeutic platelet transfusions
154. Consensus conference on platelet transfusion. The ideal platelet prescription
155. Consensus conference on platelet transfusion. How should the safety and efficacy of platelet transfusions be assured?
156. Consensus conference on platelet transfusion. Trigger factors for prophylactic platelet transfusion
157. Consensus conference on platelet transfusion. Diagnosis and treatment of patients refractory to platelet transfusions
158. Clinical and economic effects of lowering the threshold for prophylactic platelet transfusion
159. Monitoring for underutilization of RBC components and platelets